Edison have published a report on the merits of a company named VolitionRX (NYSE:VNRX). This company is developing blood test diagnostics for diseases such as Sepsis.
Sepsis is an exceedingly dangerous infectious disease that causes multiple organ failure as I know from personal experience. A few years ago I almost died from it in Kings College Hospital. The Edison report states there are 42 million cases of Sepsis worldwide every year with 11 million deaths.
Diagnosing the disease is not easy as symptoms can be mixed and treatment with antibiotics can be delayed until it’s too late. A recently publicised case in the national media was of a teenager who died from it after a minor cycling accident. Her mother has campaigned for a right to a second medical opinion in the NHS but the key is to get the diagnosis right first time and without delay. VolitionRX may provide a solution.
Sepsis is a clinical condition that occurs when the body’s immune system overreacts to a bacterial infection and begins to damage its own tissues and organs. If not diagnosed and treated quickly, it can lead to severe, often life-threatening health complications.
I personally spent three weeks in hospital after some time in the intensive care unit and suffered from intensive care neurothapy as a result which meant I had to learn to walk again. Not an experience I would like to repeat. I hope this company is successful in validating a new diagnostic for sepsis where there is clearly a large unsatisfied need.
Whether such a business is a good stock market investment is not easy to judge. They have some competitors targeting the same sector. But anyone with an interest in sepsis will find the report of interest – see https://www.edisongroup.com/research/unravelling-the-web-of-nets-in-sepsis/31224/
Roger Lawson (Twitter https://twitter.com/RogerWLawson )
You can “follow” this blog by entering your email address in the box below. You will then receive an email alerting you to new posts as they are added.